HE plasma. This is the origin of everything, and its lack of supply is the cause of everything. The complex evolution of the Catalan company Grifols In recent years. 2021 has begun and it’s time for the company’s strategic plan Grifols confirmed that the business model he was involved in was facing development challenges. The shareholders’ meeting was the starting signal of a new phase based on the search for growth and business volume in terms of public space. Regardless of whether the report was published by opportunistic individuals this Tuesday GothamThe truth is that from this commitment to diversification movements in the purest style of ‘Saksesyon’ have been derived. Grifols conspired in 2021 to increase his commitment to research as a way to avoid growth problems caused by the pharmaceutical company. Limitations of collecting blood plasma on an international scale. For Grifols, human plasma is the raw material for the development of so-called blood derivatives, which are pharmaceutical specialty products whose active ingredient comes from the plasma of healthy human donors through a suitable separation and purification process.
He is the firm’s then-co-CEO in 2021 Victor Grifols officially announced that the firm will “focus and bet on non-plasma products with a greater commitment to research”: “We want to develop a new paradigm in blood products so that we are not dependent on the US,” the firm announced in fiscal 2020, since it showed 50% of growth from new products came.
The biggest vehicles for this growth at the time were the companies Chiron, Alkahest and Gigagen, and the greater internationalization of the business (especially China, Egypt and the United States). Years later the bet was relatively unsuccessful.
Blood products are vital in various medical fields such as immunology, hepatology and intensive care, neurology, hematology and pulmonology, it cannot be said better. Plasma drugs are also applicable for the treatment of ophthalmological diseases. Because of his expertise in plasma, Grifols dreamed of vertically controlling the entire pharmacological creation process. Albert Grifols Coma-Cros was supposed to have a relevant role in new projects. The evolution of the group in the family and the entry of new generations into responsible positions was already visible.
Grifols openly acknowledged that the main goal of the commitment to the United States, Egypt and China is to increase the number of plasma donors, but he has already identified difficulties in sustaining the growth of recent years unless new paths are found for the future.
Grifols at one point proposed legal mechanisms that would allow him to purchase blood in a less regulated manner to continue his operations, as in the United States. The decrease in donations due to the pandemic triggered an alarm signal that was sought to be offset by international purchases and loans. “Without plasma, many lives will be lost due to the lack of raw materials for drug production,” Grifols warned.
The bioscience major lost weight. On the other hand, the Diagnostic division, dedicated to the production and development of devices, instrumentation and reagents for transfusion medicine, such as blood group tests or compatibility tests between donor and patient before transfusion, was on a growth trend. Stock market analysts have continued to rely on Grifols in recent years. Despite this, they are now noticing some signs. The continued acquisition of companies with banking resources and the subsequent wave of share sales are a sign that the company is being managed in a questionable manner. Despite these leveraged buyouts, their margins or profits have tended to shrink over the years. An independent audit must now confirm or reject whether the diversification strategy is the right one or a poorly controlled exit to address growth.